This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Life Science Software 2013: Markets And Opportunities

• Disease Biomarkers (Participants n=511): Disclosures from scientists and clinicians on their two main specialist software programs and their two main specialist databases, that provide the greatest support to their work on disease biomarkers; disclosures on the relative importance of specialist software and/or specialist databases and/or specialist data handling systems alongside three other general areas, as areas where innovation is most required in the disease biomarker field; End-users' estimates of the breakdown of their current annual budgets in percentage terms across six general areas, including data handling, specialist software and databases, in the disease biomarker field.

• Participant Organisations: The names, countries and applications of participant organisations

• Organisation Growth Trends: Organisations' reported plans in terms of growth in the area to which the software and databases relate (i.e. decline in activities, activities remain the same or increase in activities).

1 Background (p.5)

2 This Study (p.7)

3 Polymerase Chain Reaction (PCR) (p.10)

3.1 Study Questions

3.2 Participants

3.3 Organisations

3.4 Study Findings

3.5 Discussion

3.6 Conclusions

4 DNA Microarray (p.22)

4.1 Study Questions

4.2 Participants

4.3 Organisations

4.4 Study Findings

4.5 Discussion

4.6 Conclusions

5 DNA Sequencing (p.32)

5.1 Study Questions

5.2 Participants

5.3 Organisations

4.4 Study Findings

5.5 Discussion

5.6 Conclusions

6 Flow Cytometry (p.44)

6.1 Study Questions

6.2 Participants

6.3 Organisations

6.4 Study Findings

6.5 Discussion

6.6 Conclusions

7 Mass Spectrometry (p.56)

7.1 Study Questions

7.2 Participants

7.3 Organisations

7.4 Study Findings

7.5 Discussion

7.6 Conclusions

8 Disease Biomarkers (p.70)

8.1 Study Questions

8.2 Participants

8.3 Organisations

8.4 Study Findings

8.5 Discussion

9.6 Conclusions

9 Conclusions (p.81)

To order this report: Genomics Industry: Life Science Software 2013: Markets and Opportunities

__________________________Contact Nicolas: nicolasbombourg@reportlinker.com US: (805)-652-2626Intl: +1 805-652-2626



4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,416.85 +225.48 1.31%
S&P 500 2,021.25 +19.09 0.95%
NASDAQ 4,683.4070 +45.4130 0.98%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs